
    
      The study will be completed when the MTD and RP2D are determined. This will be either when 2
      or more patients have a DLT at a particular dose level, or when 6 patients have completed
      treatment at the highest dose level (600 mg TID). The final 3 patients enrolled at the
      highest tolerated dose will also complete PK studies.
    
  